Opendata, web and dolomites


The industrialization and market entry of a novel bioengineered hydrogel grid to standardize stem cell cultures for precision medicine.

Total Cost €


EC-Contrib. €






 Gri3D project word cloud

Explore the words cloud of the Gri3D project. It provides you a very rough idea of what is the project "Gri3D" about.

cultures    validate    base    capacity    industrial    automated    strategy    off    recurrent    cells    first    bioscience    hydrogel    single    models    health    auomates    cumulative    sa    diagnostics    initiate    maximum    verify    ambition    commercializing    customer    3d    standard    machine    platform    market    viability    line    academic    care    epfl    organ    opened    biocompatible    total    groups    microembossing    sme    tested    business    units    instrument    hydra    spin    2021    mechanism    practical    founded    handling    termed    move    patient    miniature    run    organoid    economical    translated    gri3d    annual    feasibility    revenues    pharmaceutical    switzerland    sun    precision    manufacturing    intention    tenth    entry    successful    liquid    corresponds    expand    organoids    world    leader    2016    stem    volume    clients    industry    dish    600m    possibilities    customers    technologies    gt    clinical    producing    generate    assays    introduction    medicine    endless    basic    microstructured    prototypes    company    2m   

Project "Gri3D" data sheet

The following table provides information about the project.


Organization address
postcode: 1015
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.5. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing)
2. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-03-01   to  2018-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SUN BIOSCIENCE SA CH (LAUSANNE) coordinator 50˙000.00


 Project objective

The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.

To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.

The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume. In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.

According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GRI3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GRI3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.5.;H2020-EU.2.1.3.;H2020-EU.2.3.1.;H2020-EU.2.1.2.)


Super Productive Line Printing Inkjet

Read More  

HelpingHAND (2018)

A 3D printed, affordable myoelectrical prosthetic hand of personalizeable size for optimal comfort and functionality

Read More  

HIL PT System (2017)

Revolutionary, cost effective, spatially efficient, proton therapy system for cancer treatment.

Read More